Men with obstructive median lobes treated with the UroLift® System experience symptom improvement sooner and are satisfied more quickly compared to those treated with TURP, and have fewer post-op ...
WAYNE, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE: TFX), a leading global provider of medical technologies, today announced new research from controlled and real-world ...
We have moved interventional procedures guidance 475 to become HealthTech guidance 329. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
The Expander-2 trial randomly assigned men with BPH symptoms at 23 sites in the US and Canada to receive a temporary nitinol urethral implant, Urocross Expander, or a sham procedure.
WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...
A trial of a permanent prostatic urethral stent for treatment of BPH demonstrated early success. A novel prostatic urethral stent can reduce lower urinary tract symptoms (LUTS) in men with benign ...
In a ground-breaking medical achievement, Nigeria has become the first country in West and Central Africa to successfully perform the UroLift procedure, a revolutionary treatment for benign prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results